Literature DB >> 20533156

[Partial clinical remission of chronic IgA nephropathy with therapy of tuberculosis].

J Ortmann1, H Schiffl, S M Lang.   

Abstract

HISTORY AND CLINICAL
FINDINGS: A 36-year-old patient suffered from repeated exsudative pleural effusions and renal insufficiency (serum creatinine 1.9 mg/dl) combined with glomerular erythrocyturia, proteinuria and renal hypertension. INVESTIGATIONS: The diagnosis of the underlying etiology of the pleural effusions was difficult in spite of a thorough diagnostic work-up. Pleural tuberculosis was finally detected by an interferon gamma release assay (IGRA). Kidney biopsy revealed mesangioproliferative glomerulonephritis, immunhistology showed mesangial IgA deposits. Renal insufficiency did not progress when blood pressure control was achieved. TREATMENT AND CLINICAL COURSE: The pleural effusions resolved permanently when antituberculous treatment was begun. Eight weeks after initiation of therapy normalization of kidney function (eGFR > 75 ml/min), resolution of hematuria and reduction of proteinuria were observed.
CONCLUSIONS: This report of a partial remission of IgA nephropathy by treatment of pleural tuberculosis supports the hypothesis that there may be a causal relationship between mycobacterial infections and IgA nephropathy. Georg Thieme Verlag KG Stuttgart New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20533156     DOI: 10.1055/s-0030-1255141

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

1.  Crescentic Glomerulonephritis Associated with Pulmonary Tuberculosis.

Authors:  K V Kanodia; A V Vanikar; R D Patel; K S Suthar; H L Trivedi
Journal:  J Clin Diagn Res       Date:  2016-01-01

2.  Granuloma of the labial minor salivary glands in tuberculosis.

Authors:  Adriana Handra-Luca
Journal:  J Oral Maxillofac Pathol       Date:  2018 Jan-Apr

Review 3.  Tuberculosis-associated IgA nephropathy.

Authors:  Yamei Wang; Yuhong Tao
Journal:  J Int Med Res       Date:  2018-06-04       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.